Beckman Coulter Names Scott Garrett CEO

26-Jan-2005

Beckman Coulter, Inc. announced that Scott Garrett has been named chief executive officer (CEO) of the corporation, effective February 21, 2005. Garrett, currently president and chief operating officer (COO), succeeds retiring CEO, John P. Wareham. Wareham will continue as chairman of the board until the annual shareholder meeting to be held April 7, 2005.

Wareham's intention to retire in 2005 was disclosed early last year. Garrett's appointment is the result of a recommendation made by Beckman Coulter's board of directors' transition committee, which was formed to manage the transition and chief executive officer selection process.

In a separate action, Garrett was elected to Beckman Coulter's board of directors, effective January 17, 2005. The addition of Garrett to Beckman Coulter's board raises the number of directors from 11 to 12. Garrett will stand for election at the annual stockholder meeting in April 2006.

Prior to joining Beckman Coulter in 2002, Garrett served in several leadership positions in the biomedical and clinical diagnostics industries. He served as chief executive officer of Garrett Capital Advisors and as chief executive officer for Kendro Laboratory Products, L.P. His experience includes nearly 20 years with Baxter International/American Hospital Supply Corporation. As a member of Baxter's executive team, Garrett was instrumental in their spin-out of Dade International and led the new company to achieve success in its formative years.

Other news from the department people

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper